MDA

Collaborative effort to address intestinal worms through education, medical care, health assessments, quizzes/contests in school

The effectiveness of motivating locals to address intestinal worms through education, medical care and health assessments.

Countries:

Operational research to compare the confirmatory mapping tool and xenomonitoring indicator (infectivity rate of L3 of Wuchereria bancrofti) in Monrovia to assess the necessity to implement MDA

What is the most appropriate method to evaluate the presence of W. bancrofti transmission in urban conurbations to establish if MDA is necessary for LF elimination?

Countries: Liberia

Field friendly biometry to ease cohort studies in resource-limited settings: application to the Test and Treat for onchocerciasis project in Central Cameroon

Can a biometric recognition system, in the context of “Test and Treat”, facilitate individual follow-up by linking participant data at different time-points?

Countries: Cameroon
Diseases: Loiasis | Onchocerciasis

Is Preventive Chemotherapy for NTDs Really “Pro-Poor?”: Insights from the Demographic and Health Surveys

To use DHS data from 40 countries to examine the extent to which deworming of children 1-4 years is associated with: 1) a range of individual- and family-related socioeconomic indicators, including wealth quintile and maternal education; and 2) access to health systems that could provide opportunities for deworming, independent of family-level socioeconomic status.

Countries:

Improving Mass Drug Administration After Transmission Assessment Survey Failure: Results from a Mixed Methods Study

  • What factors are associated with the availability, accessibility, and acceptability of MDA?
  • What is the impact of an adapted and tailored intervention package on effective coverage?
Countries: Ghana | Burkina Faso

Coverage Evaluation Survey and Supervisor's Coverage Tool Implementation in Kenya for Triple Drug Therapy

Coverage Evaluation Survey

Is coverage, or a combination of coverage and systematic non-compliance, more effective than a diagnostic tool at predicting when it is safe to stop triple drug therapy?

Supervisor's Coverage Tool

Is the use of the SCT during IDA feasible to implement at the sub-county scale and does it lead to increased coverage?

Countries: Kenya

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Egypt

What is the indicator(s) and accompanying monitoring and evaluation (M&E) strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?

Countries: Egypt

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Kenya

What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?

Countries: Kenya

Lymphatic Filariasis Positive-Case Follow-up After TAS 2 in Haiti

To identify the sampling strategy for positive case follow-up after TAS 2 and TAS 3 that optimizes the chances of correctly identifying evidence of ongoing transmission, while saving program resources.

Countries: Haiti

Improving Access to Mass Drug Administration for Lymphatic Filariasis Elimination using a Participatory Approach among Communities of Coastal Kenya

To assess the socio-economic factors contributing to low access to MDA, to identify the existing health services opportunities and other outlets specific to various socio-economic groups that could be used for improving access to MDA, and to develop feasible field-applicable strategies that can be used to reach groups with consistently low access to MDA.

Countries: Kenya

Pages